Entera Bio Ltd. cash flow to debt ratio of -1.50K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Entera Bio Ltd.'s free cash flow has decreased 9.62% from $-6.82M last year to $-7.48M, signaling decreasing performance

Entera Bio Ltd.'s debt to equity ratio is 0.06, which means that the company's assets are healthy financed, signaling financial stability.

Entera Bio Ltd.'s debt has increased relative to shareholder equity from 0.03 last year to 0.06 today, signaling weakened financials

Entera Bio Ltd. has a net cash position, so leverage is healthy.

Entera Bio Ltd.'s interest coverage ratio is -5.24, which means that the company struggles to meet interest obligations, signaling financial risk.

Entera Bio Ltd.'s profit margin has increased (-100.00%) in the last year from -5.27K% to 0.00%, signaling increasing performance

Entera Bio Ltd.'s short-term assets of $7.11M exceed its short-term liabilities of $2.20M

Entera Bio Ltd.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Entera Bio Ltd.'s return on equity of -147.19%, is lower than 15.00%, indicating bad performance

Entera Bio Ltd.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Entera Bio Ltd. had positive net income in only 0 out of 5 years, indicating unstable earnings

Entera Bio Ltd. has negative free cash flow, indicating the company is burning cash rather than generating it

Entera Bio Ltd. has negative free cash flow, indicating cash burn

Entera Bio Ltd.'s yearly earnings has decreased 19.89% since last year from $-9.54M to $-11.44M, signaling decreasing performance

Entera Bio Ltd.'s yearly revenue has decreased 76.80% since last year from $181.00K to $42.00K, signaling decreasing performance

ROIC -81.93% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Entera Bio Ltd.'s 3-year revenue CAGR of -32.07% is negative, indicating declining revenue over the past 3 years

Entera Bio Ltd. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Entera Bio Ltd. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Entera Bio Ltd. has insufficient data to evaluate this check.

Entera Bio Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Entera Bio Ltd. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Entera Bio Ltd. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Entera Bio Ltd. is overvalued relative to its fair value price of -0.46 based on Earnings Fair Value model

Entera Bio Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Entera Bio Ltd. has a price-to-book ratio of 21.11x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Entera Bio Ltd. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue